Tags

Type your tag names separated by a space and hit enter

ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant.
N Engl J Med. 2021 08 05; 385(6):571.NEJM

Authors+Show Affiliations

Janssen Research and Development, Beerse, Belgium fstruyf@its.jnj.com.Janssen Vaccines and Prevention, Leiden, the Netherlands.Janssen Vaccines and Prevention, Leiden, the Netherlands.

Pub Type(s)

Letter
Comment

Language

eng

PubMed ID

34289270

Citation

Struyf, Frank, et al. "ChAdOx1 nCoV-19 Vaccine Efficacy Against the B.1.351 Variant." The New England Journal of Medicine, vol. 385, no. 6, 2021, p. 571.
Struyf F, Sadoff J, Douoguih M. ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. N Engl J Med. 2021;385(6):571.
Struyf, F., Sadoff, J., & Douoguih, M. (2021). ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. The New England Journal of Medicine, 385(6), 571. https://doi.org/10.1056/NEJMc2110093
Struyf F, Sadoff J, Douoguih M. ChAdOx1 nCoV-19 Vaccine Efficacy Against the B.1.351 Variant. N Engl J Med. 2021 08 5;385(6):571. PubMed PMID: 34289270.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. AU - Struyf,Frank, AU - Sadoff,Jerald, AU - Douoguih,Macaya, Y1 - 2021/07/21/ PY - 2021/7/22/pubmed PY - 2021/8/7/medline PY - 2021/7/21/entrez SP - 571 EP - 571 JF - The New England journal of medicine JO - N Engl J Med VL - 385 IS - 6 SN - 1533-4406 UR - https://www.unboundmedicine.com/medline/citation/34289270/ChAdOx1_nCoV-19_Vaccine_Efficacy_against_the_B.1.351_Variant. L2 - https://www.nejm.org/doi/10.1056/NEJMc2110093?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -